Scientists in the UK have initiated a clinical trial designed to evaluate multiple medications simultaneously for the treatment of Alzheimer’s disease. The study, known as AD-SMART, represents a departure from traditional single-drug trial approaches by employing a multi-arm, multi-stage platform model that allows researchers to test several treatments concurrently against a control group. This methodology has been successfully applied in cancer and motor neurone disease research.
The initial phase of the trial will examine two repurposed medications: metformin, a drug commonly prescribed for type 2 diabetes, and atomoxetine, which is used to treat attention deficit hyperactivity disorder. These drugs were selected by an international expert panel based on their potential to reduce brain inflammation, a factor believed to contribute to neurodegeneration. The platform structure enables researchers to discontinue treatments that show no benefit and introduce new candidates, potentially accelerating the discovery process that has historically taken a decade or more per drug.
The study aims to recruit approximately 1,200 participants diagnosed with mild to moderate Alzheimer’s across more than 30 sites throughout the UK. Locations in Cambridgeshire, Surrey, London, Southampton, and Edinburgh are currently accepting participants. Researchers plan to complete evaluation of the initial drugs in 2030, with additional treatments likely to be incorporated during that timeframe. All participants will undergo regular health assessments, including cognitive testing, to measure treatment effectiveness.
Alzheimer’s remains the most prevalent form of dementia in the UK, affecting approximately 600,000 people. The trial is being conducted by the UK Dementia Research Institute and Alzheimer’s Research UK, with support from multiple government and health research organizations. Officials emphasize that identifying effective treatment options is urgent for the growing population living with the disease.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI